+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of HCV infection in an academic medical center The experience with interferon/ribavirin

Treatment of HCV infection in an academic medical center The experience with interferon/ribavirin

Hepatology 32(4 Pt 2): 566A, October

(PDF 0-2 workdays service: $29.90)

Accession: 035980447

Download citation: RISBibTeXText

Related references

Initial experiences with interferon and ribavirin for hepatitis C; tolerability of treatment in an academic center. Hepatology 28(4 PART 2): 716A, 1998

Outcome of treatment with peg-interferon and ribavirin in HIV-HCV co-infected patients: "real life" single center experience. Harefuah 151(12): 684-7, 721, 720, 2013

Experience with etanercept in an academic medical center: are infection rates increased?. Arthritis and Rheumatism 47(1): 17-21, 2002

Early HCV-RNA decline during treatment with PEG-interferon alfa-2b plus ribavirin or conventional interferon alfa 2b plus ribavirin Analysis of 80 patients treated at a single center. Hepatology 34(4 Pt 2): 217A, October, 2001

Effects of HCV treatment on HIV course Preliminary results of the ANRS HC 02-ribavic study A randomized, controlled trial of pegylated interferon-alpha2b with ribavirin vs interferon-alpha2b with ribavirin for the treatment of chronic HCV in HIV co-infection. Hepatology 36(4 Part 2): 585A, October, 2002

Efficacy and tolerability of combination therapy with interferon-alfa plus ribavirin in patients with chronic hepatitis C virus infection: a single-center study in relapsers and nonresponders to previous treatment with high-dose interferon-alfa monotherapy. Current Therapeutic Research, Clinical and Experimental 64(3): 140-150, 2003

Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience. Scandinavian Journal of Gastroenterology 51(3): 337-343, 2016

A multi-center trial using daily induction dose interferon alpha 2b plus ribavirin followed by daily interferon alpha 2b + ribavirin in patients with chronic hepatitis C who are treatment naive. Hepatology 32(4 Pt 2): 556A, October, 2000

The experience of an academic medical center with endovascular treatment of abdominal aortic aneurysms. American Journal of Surgery 176(2): 198-202, 1998

A multi-center, randomized, open-label study of the safety and efficacy of interferon alpha-2b plus ribavirin for the treatment of HCV infection in HIV-infected persons. Hepatology 34(4 Pt 2): 594A, October, 2001

Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. Infection 33(1): 25-29, 2005

PEGYLATED INTERFERON AND RIBAVIRIN FOR TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: a single-liver transplant center experience in Brazil. Arquivos de Gastroenterologia 52(3): 216-221, 2016

The combination of pegylated interferon and ribavirin in the treatment of chronic hepatitis C infection Preliminary report of a single centre experience. Gut 50(Supplement 2): A117-A118, April, 2002

Melanocyte-keratinocyte transplantation procedure in the treatment of vitiligo: the experience of an academic medical center in the United States. Journal of the American Academy of Dermatology 66(5): 785-793, 2012